BSECompany Update4 Nov 2026 · 4 Nov 2026, 06:34 pm

Intimation regarding execution of Agreement by Wholly Owned Subsidiary of the Company

Bacil Pharma Ltd · 524516

✦ AI SummaryExpansion

Bacil Pharma Ltd's wholly owned subsidiary, Bacil Research and Development Private Limited, has entered into an agreement with Efdee Pharma Private Limited for research and development activities relating to pharmaceutical products, with an estimated cost of ₹35,00,00,000.

Analysis Scores

Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Bacil Pharma Ltd - 524516 - Intimation Regarding Execution Of Agreement By Wholly Owned Subsidiary Of The Company

Attachments (1)

📄

4c7a135e-2a59-4c0a-b8fe-0fb3bc2a7d7f.pdf

pdf

Download →
View document text
Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099 Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541, Tel/Fax: 22618327 Date: 04/11/2026 The Department of Corporate Services, BSE Limited, P. J. Towers, Dalal Street, Mumbai – 400001. Scrip Code: 524516 Scrip ID: BACPHAR Subject: Intimation regarding execution of Agreement by Wholly Owned Subsidiary of the Company Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Bacil Research and Development Private Limited, a wholly owned subsidiary of Bacil Pharma Limited (“the Company”), has entered into an agreement with Efdee Pharma Private Limited for undertaking research and development activities relating to pharmaceutical products. The project shall involve research and development of pharmaceutical products, including pellets, granules, powders, tablets and capsules. The total estimated cost of the project shall be ₹35,00,00,000/- (Rupees Thirty Five Crore Only). In this regard, the Company has authorised Mrs. Chaitali Shah, Director, to execute the aforesaid agreement and undertake all necessary acts, deeds and things, including signing and executing documents and completing all formalities in connection with the said project on behalf of the wholly owned subsidiary. The details of the aforesaid transaction, as required under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with the applicable SEBI circulars, are enclosed as Annexure A. You are requested to take the above information on record. Thanking you, Yours faithfully, For Bacil Pharma Limited Chaitali Kalpataru Shah Managing Director Din: 11167778 Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099 Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541, Tel/Fax: 22618327 Suggested Annexure A – Disclosure under Regulation 30 Particulars Details Name of the entity entering into the Bacil Research and Development Private Limited agreement Relationship with the listed entity Wholly owned subsidiary of Bacil Pharma Limited Name of the other party Efdee Pharma Private Limited Nature of agreement Agreement for research and development of pharmaceutical products Scope of project Research and development of pellets, granules, powders, tablets and capsules Estimated project cost ₹35,00,00,000/- (Rupees Thirty Five Crore Only) Authorised representative Mrs. Chaitali Shah, Director Date of agreement 04/11/2026 For Bacil Pharma Limited Chaitali Kalpataru Shah Managing Director Din: 11167778